Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026
Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Fineline Cube Apr 2, 2026
Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Apr 2, 2026
Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Fineline Cube Apr 2, 2026
Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Fineline Cube Apr 2, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Fineline Cube Apr 2, 2026
Drug Policy / Regulatory

CDE Releases 76th Batch of Chemical Generic Reference Preparations

Fineline Cube Nov 17, 2023

The Center for Drug Evaluation (CDE) has released the 76th batch of chemical generic reference...

Company Drug

Yipinhong Pharmacy’s AR882 Shows Promise in Gout Treatment in Phase II Study

Fineline Cube Nov 17, 2023

China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced positive data from a Phase II...

Company Drug

Easton Pharmaceutical Receives FDA Approval for Generic Nalmefene

Fineline Cube Nov 17, 2023

Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...

Deals R&D

University of Hong Kong to Host Infectious Disease Labs by UN’s Vaccine Institute and Cambridge University

Fineline Cube Nov 17, 2023

The University of Hong Kong (HKU) is poised to host new infectious disease laboratories established...

Company

BeiGene Ltd Opens Global Industrialization Base for Small-Molecule Drugs in Suzhou

Fineline Cube Nov 17, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the inauguration of its small-molecule...

Company Drug

Visen Pharmaceuticals Reports Positive Phase II Results for TransCon CNP in Achondroplasia

Fineline Cube Nov 17, 2023

Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma A/S (NASDAQ: ASND) and Chinese healthcare...

Company Deals

Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services

Fineline Cube Nov 17, 2023

Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an...

Company Drug

Vertex Pharmaceuticals and CRISPR Therapeutics Receive Conditional Approval for CRISPR Gene-Editing Therapy

Fineline Cube Nov 17, 2023

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) have received conditional approval from the...

Company Deals

Q32 Bio Reclaims Development Rights to Anti-IL-7Rα Biologic from Amgen

Fineline Cube Nov 17, 2023

Biotechnology firm Q32 Bio has announced its decision to reclaim full development and commercial rights...

Company Deals

Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry

Fineline Cube Nov 16, 2023

Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum...

Company Drug

SinoMab BioScience’s Suciraslimab IND Accepted for Review by China’s NMPA

Fineline Cube Nov 16, 2023

SinoMab BioScience Ltd (HKG: 3681), a Hong Kong-based biotechnology company, has announced that the National...

Company

Shanghai Henlius Biotech Reports 84.0% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Nov 16, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published...

Company Medical Device

Sino Medical Sciences Technology’s HT Supreme Stent Gains Brazilian Market Approval

Fineline Cube Nov 16, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108) a leading China-based medical device company, has announced...

Company Deals

Gilead’s Kite Expands Partnership with Arcellx for Innovative Cell Therapies

Fineline Cube Nov 16, 2023

Gilead (NASDAQ: GILD), a leading biopharmaceutical company, has announced an expansion of its 2022 partnership...

Company Deals

AbbVie Partners with Sinopharm to Enhance Novel Drug Accessibility and Patient Management

Fineline Cube Nov 16, 2023

US pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a strategic partnership with Sinopharm Group...

Company Drug

Fujian Cosunter’s COVID-19 Therapy GST-HG171/Ritonavir NDA Accepted by NMPA

Fineline Cube Nov 16, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that its...

Company Deals

Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment

Fineline Cube Nov 16, 2023

Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US...

Company Deals

Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal

Fineline Cube Nov 16, 2023

Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal...

Company Drug

China’s NMPA Accepts EOC Pharma Group’s Filing for Vascepa (Icosapent Ethyl) for Review

Fineline Cube Nov 15, 2023

The China-based EOC Pharma Group has achieved a significant milestone with the National Medical Products...

Company Deals

Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition

Fineline Cube Nov 15, 2023

The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...

Posts pagination

1 … 422 423 424 … 645

Recent updates

  • RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors
  • Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies
  • Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal
  • Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer
  • NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors

Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Company Deals

Sanli Pharmaceutical Transfers Marketing Rights for 16 Drugs to Hanfang Pharmaceutical in RMB 2 Million Deal

Company Drug

Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.